Hyperhomocysteinemia (HHcy) has been considered as a risk factor for cardiovascular disease, Alzheimer's disease, nonalcoholic fatty liver, and many other pathological conditions. Vitamin B6, Vitamin B12, and folate have been used to treat HHcy in clinics. However, at present, clinical therapies of HHcy display unsatisfactory effects. Here, we would like to explore a new mechanism involved in homocysteine (Hcy) metabolic disorders and a novel target for HHcy treatment. The key enzymes involved in Hcy metabolism deserve more insightful investigation. Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme regulating the intracellular Hcy metabolism. Until now, the effect of post-translational modification on the bioactivity of MTHFR still remains unclear. This study aimed at exploring the relationship between MTHFR S-sulfhydration and its bioactivity, and at identifying the contribution of an elevated Hcy level on MTHFR bioactivity.
Results:
By both in vivo and in vitro studies, we observed the following results: (i) The bioactivity of MTHFR was positively associated with its S-sulfhydration level; (ii) MTHFR was modified at Cys32, Cys130, Cys131, Cys193, and Cys306 by S-sulfhydration under physiological conditions; (iii) Hydrogen sulfide (H2S) deficiency caused the decrease of MTHFR S-sulfhydration level and bioactivity in HHcy, which resulted in further aggravation of HHcy; and (iv) H2S donors reversed the decreased bioactivity of MTHFR in HHcy, thus reducing the excessive Hcy level.
Innovation and Conclusion:
Our study suggested that H2S could improve MTHFR bioactivity by S-sulfhydration, which might provide a candidate therapeutic strategy for HHcy. Antioxid. Redox Signal. 36, 1–14.
Get full access to this article
View all access options for this article.
References
1.
BeheraJ, GeorgeAK, VoorMJ, TyagiSC, and TyagiN. Hydrogen sulfide epigenetically mitigates bone loss through OPG/RANKL regulation during hyperhomocysteinemia in mice. Bone, 114: 90–108, 2018.
2.
BhatiaM, ThakurJ, SuyalS, OnielR, ChakrabortyR, PradhanS, SharmaM, SenguptaS, LaxmanS, MasakapalliSK, and BachhawatAK. Allosteric inhibition of MTHFR prevents futile SAM cycling and maintains nucleotide pools in one-carbon metabolism. J Biol Chem, 295: 16037–16057, 2020.
3.
ChengZ, ShenX, JiangX, ShanH, CiminiM, FangP, JiY, ParkJY, DrosatosK, YangX, KevilCG, KishoreR, and WangH. Hyperhomocysteinemia potentiates diabetes-impaired EDHF-induced vascular relaxation: role of insufficient hydrogen sulfide. Redox Biol, 16: 215–225, 2018.
4.
De MattiaE and ToffoliG. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur J Cancer, 45: 1333–1351, 2009.
FlanniganKL, AgborTA, BlacklerRW, KimJJ, KhanWI, VerduEF, FerrazJG, and WallaceJL. Impaired hydrogen sulfide synthesis and IL-10 signaling underlie hyperhomocysteinemia-associated exacerbation of colitis. Proc Natl Acad Sci U S A, 111: 13559–13564, 2014.
8.
FroeseDS, KopecJ, RembezaE, BezerraGA, OberholzerAE, SuormalaT, LutzS, ChalkR, BorkowskaO, BaumgartnerMR, and YueWW. Structural basis for the regulation of human 5,10-methylenetetrahydrofolate reductase by phosphorylation and S-adenosylmethionine inhibition. Nat Commun, 9: 2261, 2018.
9.
FroeseDS, HuemerM, SuormalaT, BurdaP, CoelhoD, GuéantJL, LandoltMA, KožichV, FowlerB, and BaumgartnerMR. Mutation update and review of severe methylenetetrahydrofolate reductase deficiency. Hum Mutat, 37: 427–438, 2016.
10.
GarcíaTevijanoER, BerasainC, RodríguezJA, CorralesFJ, AriasR, Martín-DuceA, CaballeríaJ, MatoJM, and AvilaMA. Hyperhomocysteinemia in liver cirrhosis: mechanisms and role in vascular and hepatic fibrosis. Hypertension, 38: 1217–1221, 2001.
11.
GjesdalCG, VollsetSE, UelandPM, RefsumH, DrevonCA, GjessingHK, and TellGS. Plasma total homocysteine level and bone mineral density: the Hordaland Homocysteine Study. Arch Intern Med, 166: 88–94, 2006.
12.
HasanT, AroraR, BansalAK, BhattacharyaR, SharmaGS, and SinghLR. Disturbed homocysteine metabolism is associated with cancer. Exp Mol Med, 51: 1–13, 2019.
13.
HuangX, LiD, ZhaoQ, ZhangC, RenB, YueL, DuB, GodfreyO, WangX, and ZhangW. Association between BHMT and CBS gene promoter methylation with the efficacy of folate therapy in patients with hyperhomocysteinemia. J Hum Genet, 64: 1227–1235, 2019.
14.
KayeAD, JehaGM, PhamAD, FullerMC, LernerZI, SibleyGT, CornettEM, UritsI, ViswanathO, and KevilCG. Folic acid supplementation in patients with elevated homocysteine levels. Adv Ther, 37: 4149–4164, 2020.
15.
KimuraH. Signalling by hydrogen sulfide and polysulfides via protein S-sulfuration. Br J Pharmacol, 177: 720–733, 2020.
16.
KimuraH. Signaling by hydrogen sulfide (HS) and polysulfides (HS) in the central nervous system. Neurochem Int, 126: 118–125, 2019.
17.
KimuraY, MikamiY, OsumiK, TsuganeM, OkaJ, and KimuraH. Polysulfides are possible H2S-derived signaling molecules in rat brain. FASEB J, 27: 2451–2457, 2013.
18.
KutzbachC and StokstadEL. All activities of the enzyme are strongly inhibited by S-adenosylmethionine. Biochim Biophys Acta, 250: 459–477, 1971.
19.
LightfootTJ, JohnstonWT, PainterD, SimpsonJ, RomanE, SkibolaCF, SmithMT, AllanJM, and TaylorGM. Genetic variation in the folate metabolic pathway and risk of childhood leukemia. Blood, 115: 3923–3929, 2010.
20.
LuoC, JiD, LiY, CaoY, ZhangS, YanW, XueK, ChaiJ, WuY, LiuH, and WangW. Abnormal nitration and S-sulfhydration modification of Sp1-CSE-H2S pathway trap the progress of hyperhomocysteinemia into a vicious cycle. Free Radic Biol Med, 164: 20–33, 2021.
21.
MajumderA, SinghM, BeheraJ, TheilenNT, GeorgeAK, TyagiN, MetreveliN, and TyagiSC. Hydrogen sulfide alleviates hyperhomocysteinemia-mediated skeletal muscle atrophy via mitigation of oxidative and endoplasmic reticulum stress injury. Am J Physiol Cell Physiol, 315: C609–C622, 2018.
22.
MarkandS, SaulA, RoonP, PrasadP, MartinP, RozenR, GanapathyV, and SmithSB. Retinal ganglion cell loss and mild vasculopathy in methylene tetrahydrofolate. Invest Ophthalmol Vis Sci, 56: 2684–2695, 2015.
MengG, MaY, XieL, FerroA, and JiY. Emerging role of hydrogen sulfide in hypertension and related cardiovascular diseases. Br J Pharmacol, 172: 5501–5511, 2015.
25.
MikaelLG, GenestJ, and RozenR. Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic. Circ Res, 98: 564–571, 2006.
26.
MollS and VargaEA. Homocysteine and MTHFR mutations. Circulation, 132: e6–e9, 2015.
27.
MorettiR and CarusoP. The controversial role of homocysteine in neurology: from labs to clinical practice. Int J Mol Sci, 20: 231, 2019.
28.
NishiA, NumataS, TajimaA, KinoshitaM, KikuchiK, ShimoderaS, TomotakeM, OhiK, HashimotoR, ImotoI, TakedaM, and OhmoriT. Meta-analyses of blood homocysteine levels for gender and genetic association studies of the MTHFR C677T polymorphism in schizophrenia. Schizophr Bull, 40: 1154–1163, 2014.
29.
PaulBD and SnyderSH. H2S: a Novel gasotransmitter that signals by sulfhydration. Trends Biochem Sci, 40: 687–700, 2015.
30.
SelhubJ. Homocysteine metabolism. Annu Rev Nutr, 19: 217–246, 1999.
31.
SenN, PaulBD, GadallaMM, MustafaAK, SenT, XuR, KimS, and SnyderSH. Hydrogen sulfide-linked sulfhydration of NF-kappaB mediates its antiapoptotic actions. Mol Cell, 45: 13–24, 2012.
32.
SenU, SathnurPB, KunduS, GivvimaniS, ColeyDM, MishraPK, QipshidzeN, TyagiN, MetreveliN, and TyagiSC. Increased endogenous H2S generation by CBS, CSE, and 3MST gene therapy improves ex vivo renovascular relaxation in hyperhomocysteinemia. Am J Physiol Cell Physiol, 303: C41–C51, 2012.
33.
SeshadriS, BeiserA, SelhubJ, JacquesPF, RosenbergIH, D'AgostinoRB, WilsonPW, and WolfPA. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med, 346: 476–483, 2002.
34.
SunHJ, XiongSP, CaoX, CaoL, ZhuMY, WuZY, and BianJS. Polysulfide-mediated sulfhydration of SIRT1 prevents diabetic nephropathy by suppressing phosphorylation and acetylation of p65 NF-κB and STAT3. Redox Biol, 38: 101813, 2021.
35.
SunX, ZhaoD, LuF, PengS, YuM, LiuN, SunY, DuH, WangB, ChenJ, DongS, LuF, and ZhangW. Hydrogen sulfide regulates muscle RING finger-1 protein S-sulfhydration at Cys44 to prevent cardiac structural damage in diabeti cardiomyopathy. Br J Pharmacol, 177: 836–856, 2020.
36.
TianH, TianD, ZhangC, WangW, WangL, GeM, HouQ, and ZhangW. Efficacy of folate therapy in patients with hyperhomocysteinemia. J Am Coll Nutr, 36: 528–532, 2017.
37.
TigheP, WardM, McNultyH, FinneganO, DunneA, StrainJ, MolloyAM, DuffyM, PentievaK, and ScottJM. A dose-finding trial of the effect of long-term folate intervention: implications for food fortification policy1. Am J Clin Nutr, 93: 11–18, 2011.
WaldDS, LawM, and MorrisJK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ, 325: 1202, 2002.
40.
WallaceJL and WangR. Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter. Nat Rev Drug Discov, 14: 329–345, 2015.
41.
XieL, GuY, WenM, ZhaoS, WangW, MaY, MengG, HanY, WangY, LiuG, MoorePK, WangX, WangH, ZhangZ, YuY, FerroA, HuangZ, and JiY. Hydrogen sulfide induces Keap1 S-sulfhydration and suppresses diabetes-accelerated atherosclerosis via Nrf2 activation. Diabetes, 65: 3171–3184, 2016.
42.
YamadaK, StrahlerJR, AndrewsPC, and MatthewsRG. Regulation of human methylenetetrahydrofolate reductase by phosphorylation. Proc Natl Acad Sci U S A, 102: 10454–10459, 2005.
43.
YanY, WuX, WangP, ZhangS, SunL, ZhaoY, ZengG, LiuB, XuG, LiuH, WangL, WangX, and JiangC. Homocysteine promotes hepatic steatosis by activating the adipocyte lipolysis in a HIF1α-ERO1α-dependent oxidative stress manner. Redox Biol, 37: 101742, 2020.
44.
ZaricBL, ObradovicM, BajicV, HaidaraMA, JovanovicM, and IsenovicER. Homocysteine and Hyperhomocysteinaemia. Curr Med Chem, 26: 2948–2961, 2019.
45.
ZhengY, RamsamoojS, LiQ, JohnsonJL, YaronTM, SharraK, and CantleyLC. Regulation of folate and methionine metabolism by multisite phosphorylation of human methylenetetrahydrofolate reductase. Sci Rep, 9: 4190, 2019.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
